Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.
Retrieved on:
среда, января 5, 2022
Wilms' tumor, Bioverativ, Therapy, Congenital adrenal hyperplasia, Drug discovery, Acromegaly, Drug Quality and Security Act, Degenerative disease, Form 10-K, Genzyme, Endocrinology, Research, Patient, Genetics, Faculdade de Medicina da Universidade Federal de Minas Gerais, Securities Exchange Act of 1934, Department of Genetics, University of Cambridge, Gaucher, Spark Therapeutics, Voretigene neparvovec, Disease, Congenital hyperinsulinism, SEC, ACTH, Enzyme replacement therapy, SAN, GLOBE, Securities Act of 1933, Annual report, Industry, Gaucher's disease, Carcinoid syndrome, Pharmaceutical industry, Universiade
Dr. Vivaldi comes to Crinetics with over two decades of experience as a physician and industry executive with deep expertise commercializing pharmaceuticals, especially those treating rare and orphan diseases, in the U.S. and globally.
Key Points:
- Dr. Vivaldi comes to Crinetics with over two decades of experience as a physician and industry executive with deep expertise commercializing pharmaceuticals, especially those treating rare and orphan diseases, in the U.S. and globally.
- Dr. Vivaldi is currently the president and chief executive officer of Sigilon Therapeutics, Inc., where he also serves as a member of the company's board of directors.
- While each rare disease impacts only a small number of people, they collectively affect an estimated 25-30 million Americans.
- Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.